Skip to main content
. 2010 Apr 26;95(9):1473–1480. doi: 10.3324/haematol.2010.021808

Figure 3.

Figure 3.

Clinical significance of transcription factor (TF) mutations in MDS/MPN. Kaplan-Meier estimates of (A) overall survival and (B) progression-free survival for 127 MDS/MPN patients with or without mutations of transcription factors. Overall survival was significantly lower in mutation-positive compared to mutation-negative cases (P=0.0190, log-rank test). Kaplan-Meier estimates of (C) overall survival and (D) progression-free survival for each specific mutation. Patients with CEBPA, NPM1 or WT1 mutations collectively showed a highly significant shorter overall survival (P<0.001) and progression-free survival (P<0.001) compared to cases without transcription factor mutations. Considering each gene individually, the P values for CEBPA, NPM1 and WT1 were 0.0047, 0.0024 and 0.0583, respectively, for overall survival and 0.0096, 0.0018 and 0.174, respectively for progression-free survival.